menu
    • menu
    [{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"15","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"15","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Xspray Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."}]

    Find Clinical Drug Pipeline Developments & Deals by Axis Clinicals Ltd.

    Menu

    Axis Clinicals Ltd.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Xspray Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Sub...

                            Details : Dasatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2022

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Xspray Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vincristine Sulfate

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Maligna...

                            Details : Vincristine Sulfate is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Diseases.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 28, 2020

                            Lead Product(s) : Vincristine Sulfate

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Tri...

                            Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 04, 2019

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amphotericin B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Aurobindo Pharma Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

                            Details : Amphotericin B is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leishmaniasis, Visceral.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 17, 2018

                            Lead Product(s) : Amphotericin B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Aurobindo Pharma Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

                            Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 12, 2016

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Imp...

                            Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 10, 2016

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

                            Details : Pralatrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 03, 2015

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed

                            Axis Clinicals Ltd.

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignanc...

                            Details : Pralatrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2014

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Acrotech Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth